Want to see TEVA full AI Analyst Report?
Earnings Data
Report Date
Jul 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.06Last Year’s EPS
0.66Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive strategic and operational picture: strong growth and momentum in the innovative portfolio (AUSTEDO, UZEDY, AJOVY), improving gross margins and cash generation, clear progress on transformation savings and a disciplined, accretive acquisition (Emalex) aligned to the Pivot to Growth strategy. Near-term headwinds include generics comparatives (loss of REVLIMID), accounting and expense impacts from the Emalex asset purchase in 2026, margin reinvestment and some channel/inventory timing uncertainty (notably AUSTEDO destocking and IRA timing). Pipeline milestones present upside but carry binary clinical risk. On balance, the positives — accelerating innovative growth, margin trajectory, balance sheet improvement and clear execution plans — outweigh the near-term and manageable negatives.Company Guidance
Solid Top-Line and Underlying Revenue Growth (Adjusted Basis)
Reported revenue of approximately $4.0 billion in Q1 2026 (down ~1% in local currency vs. Q1 2025). On an underlying like-for-like basis (excluding the Japan divestment and generic REVLIMID), management reports revenue growth of ~7%.
Strong Growth in Innovative Portfolio
Innovative products drove robust growth: AUSTEDO U.S. revenue $559M, up 41% year-over-year; UZEDY revenue up 62% to $63M; AJOVY grew 35% to $196M. Innovative portfolio now represents >20% of company revenue (up from ~9% in 2022).
Improving Margin Profile and Gross Margin Beat
Q1 non-GAAP gross margin of 52.9%, above management expectations. Company reiterates structural margin improvement trajectory with 2026 non-GAAP gross margin guidance of 54.5%–55.5% and an anticipated gross margin above 60% by 2030 as the portfolio shifts toward innovative, higher-margin products.
Profitability and Cash Flow Progress
Adjusted EBITDA reported at ~$1.1 billion (up ~2% YoY on a reported basis). Non-GAAP EPS was $0.53 (versus $0.52 a year ago). Free cash flow improved to $188 million in Q1 (from $107M last year), roughly a ~76% increase year-over-year for the quarter.
Balance Sheet and Leverage Progress
Net debt to EBITDA improved to ~2.42x at quarter-end. Management remains on track for a target net debt/EBITDA of <2.0x by 2027 and notes progress toward an investor-grade credit profile.
On Track with Transformation Savings
Pivot to Growth transformation programs targeting $700 million of savings by 2027. Management expects ~2/3 of the total savings to be realized by the end of 2026 and has recorded restructuring charges and cash outflows consistent with the program (e.g., ~$205M restructuring costs in 2025; additional $25M in Q1 2026).
Emalex Acquisition Aligned with Strategy
Agreement to acquire Emalex: $700M upfront cash plus up to $200M in commercial milestones. Ecopipam is described as first-in-class for Tourette syndrome, with an expected product gross margin profile of ~80%, regulatory filing expected H2 2026 and launch contribution beginning in 2027; acquisition intended to be accretive to non-GAAP EPS starting in 2028.
Biosimilars and Generics Positioning
Biosimilar build-out: 11 biosimilars currently on the market, 4 additional expected that cover ~$16B of originator sales through 2027, and a further 9 planned covering ~$58B thereafter — demonstrating growing contribution from higher-value generics/biosimilars.
Robust R&D/Pipeline Milestone Cadence
Multiple near-term pipeline catalysts: seven milestone readouts this year (including duvakitug maintenance, anti–IL-15 vitiligo readout in H1, celiac readout in H2, DARI Phase III events, emrusolmin futility analysis and PD-1–IL-2 data). Management estimates the pipeline opportunities could amount to >$10B peak sales.
TEVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TEVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $31.62 | $35.38 | +11.89% |
Jan 28, 2026 | $32.53 | $33.21 | +2.09% |
Nov 05, 2025 | $20.46 | $24.60 | +20.23% |
Jul 30, 2025 | $16.54 | $16.83 | +1.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Teva Pharmaceutical Industries Limited (TEVA) report earnings?
Teva Pharmaceutical Industries Limited (TEVA) is schdueled to report earning on Jul 29, 2026, Before Open (Confirmed).
What is Teva Pharmaceutical Industries Limited (TEVA) earnings time?
Teva Pharmaceutical Industries Limited (TEVA) earnings time is at Jul 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TEVA EPS forecast?
TEVA EPS forecast for the fiscal quarter 2026 (Q2) is 0.06.
